Agenus has commenced the first clinical trial of its latest advanced cancer treatment, AutoSynVax (ASV). Throughout the trial the neoantigen vaccine will be combined with QS-21 Stimulon. The treatment has presented evidence that it mediates tumor control and lasting immune memory in murine models of care. This success may be continued with checkpoint modifiers throughout clinical trial phases.